[go: up one dir, main page]

AR033862A1 - MEDICINAL FORMULATION CONTAINING A MUSCARINIC AGONIST AGENT - Google Patents

MEDICINAL FORMULATION CONTAINING A MUSCARINIC AGONIST AGENT

Info

Publication number
AR033862A1
AR033862A1 ARP020100515A ARP020100515A AR033862A1 AR 033862 A1 AR033862 A1 AR 033862A1 AR P020100515 A ARP020100515 A AR P020100515A AR P020100515 A ARP020100515 A AR P020100515A AR 033862 A1 AR033862 A1 AR 033862A1
Authority
AR
Argentina
Prior art keywords
formulation containing
muscarinic agonist
medicinal formulation
agonist agent
talsaclidine
Prior art date
Application number
ARP020100515A
Other languages
Spanish (es)
Inventor
Karoline Dr Bechtold-Peters
Thomas Friedl
Michael Dr Walz
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of AR033862A1 publication Critical patent/AR033862A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Formulación de medicamento que contiene talsaclidina 1', que consta de un núcleo que contiene la sustancia activa talsaclidina y un revestimiento de película que envuelve a éste núcleo.Medication formulation containing 1 'talsaclidine, which consists of a nucleus containing the active substance talsaclidine and a film coating that envelops this nucleus.

ARP020100515A 2001-02-15 2002-02-15 MEDICINAL FORMULATION CONTAINING A MUSCARINIC AGONIST AGENT AR033862A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10106971A DE10106971A1 (en) 2001-02-15 2001-02-15 Drug formulation containing a muscarinic agonist

Publications (1)

Publication Number Publication Date
AR033862A1 true AR033862A1 (en) 2004-01-07

Family

ID=7674095

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020100515A AR033862A1 (en) 2001-02-15 2002-02-15 MEDICINAL FORMULATION CONTAINING A MUSCARINIC AGONIST AGENT

Country Status (9)

Country Link
EP (1) EP1361871A2 (en)
JP (1) JP2004518710A (en)
AR (1) AR033862A1 (en)
AU (1) AU2002247705A1 (en)
CA (1) CA2434976A1 (en)
DE (1) DE10106971A1 (en)
MX (1) MXPA03007272A (en)
UY (1) UY27170A1 (en)
WO (1) WO2002064124A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ597109A (en) 2007-03-29 2013-01-25 Daiichi Sankyo Co Ltd Tablet composition having favorable dissolution property useful as an anticoagulant
WO2010033045A1 (en) * 2008-09-16 2010-03-25 Igor Anatolievich Pomytkin Compositions and methods for prevention or treatment of beta amyloid deposition
EP2548556B1 (en) 2010-03-19 2016-08-10 Daiichi Sankyo Company, Limited Method for improving dissolvability of anticoagulant
CA2844604C (en) 2011-08-10 2017-07-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ethanediamide derivatives

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8817121U1 (en) * 1988-11-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim New quinuclidines
AU5716898A (en) * 1997-01-08 1998-08-03 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
AU6896098A (en) * 1997-04-11 1998-11-11 Eli Lilly And Company Method for treating schizophrenia
WO1998046601A1 (en) * 1997-04-11 1998-10-22 Eli Lilly And Company Composition for treating pain
DE19851126A1 (en) * 1998-11-06 2000-05-11 Boehringer Ingelheim Pharma Use of talsaclidine for treating schizophrenia

Also Published As

Publication number Publication date
WO2002064124A2 (en) 2002-08-22
UY27170A1 (en) 2002-09-30
WO2002064124A3 (en) 2002-12-05
CA2434976A1 (en) 2002-08-22
DE10106971A1 (en) 2002-08-29
JP2004518710A (en) 2004-06-24
EP1361871A2 (en) 2003-11-19
AU2002247705A1 (en) 2002-08-28
MXPA03007272A (en) 2003-12-04

Similar Documents

Publication Publication Date Title
ATE293995T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS THAT PROMOTE DRUG ABSORPTION
NO20016108D0 (en) Controlled release and taste masking oral pharmaceutical compositions
FR2774288B1 (en) GASTROPROTEGED OMEPRAZOLE MICROGRANULES, PROCESS FOR OBTAINING AND PHARMACEUTICAL PREPARATIONS
MA23608A1 (en) DOSAGE FORM II OF MULTIPLE TABLET UNIT
DE60335557D1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINED AN OPIOIDANAL GETIC
CY1116429T1 (en) LEATHER FOR LEATHER AND INTERMEDIATE ADMINISTRATION OF ACTIVE INGREDIENTS
DZ2964A1 (en) New substituted diphenylureas, and pharmaceutical compositions containing them.
WO2002072033A3 (en) Chronotherapeutic dosage forms containing glucocorticosteroid
DE69942154D1 (en) MEDICATION-COMPATIBLE COMPOSITION IN AEROSOL FORM
ES2192226T3 (en) ORAL PHARMACEUTICAL COMPOSITION CONTAINING ANTIMICROBIAL ACTIVE AGENTS AND PROLONGED LIBERATION PANTOPRAZOL.
SE0003449D0 (en) Anticancer compositions
BRPI0412029A (en) formulations for coated microprojections containing nonvolatile counterions
PL337794A1 (en) Pharmaceutic agent for oral administration containing an active substance and cyclodextrin
BRPI0408655A (en) formulations comprising an active agent and cocoa powder and their use
MA26491A1 (en) SELECTIVE COX-2 INHIBITOR COMPOUNDS, ANTI-INFLAMMATORY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
ATE469644T1 (en) PHARMACEUTICAL PREPARATION CONTAINING N-Ä2-(1,6, 7,8-TETRAHYDRO-2H-INDENOÄ5,4 BUFURAN-8-YL)ETHYLUPROPIONAMIDE COATED WITH A COPOLYVIDONE-CONTAINING, POLYETHYLENE GLYCOL-FREE COATING
DE69907926D1 (en) 1,2,4-TRIAZOL-3-THION COMPOUNDS
ES2113985T3 (en) COATING MATERIAL FOR DRUG FORMS OF ORAL ADMINISTRATION.
AR033862A1 (en) MEDICINAL FORMULATION CONTAINING A MUSCARINIC AGONIST AGENT
DE60002089D1 (en) LOW-DOSED TABLETS AND METHOD FOR THE PRODUCTION THEREOF
ATE158172T1 (en) POWDER PHARMACEUTICAL COMPOSITION
BR0202759A (en) Modified release pharmaceutical composition containing bupropion as active substance
JPH11279077A5 (en)
FR2826367B1 (en) NOVEL 4- (4-CYANOBENZOYL) PHENYL] GLYCOPYRANOSIDE DERIVATIVES, USE AS MEDICAMENT, PROCESS FOR OBTAINING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Legal Events

Date Code Title Description
FA Abandonment or withdrawal